GlaxoSmithKline will cut 240 to 250 jobs at sites in Pennsylvania and the United Kingdom, according to EndPoints News.
The layoffs come as the drugmaker works to revise its research and development strategy under its new R&D chief Hal Barron.
Most of the job cuts will affect chemists at its facility in Upper Providence, Pa., as well as some administrative roles.
A few R&D jobs at its facility in Stevenage, U.K., also will be eliminated.
Read the full report here.